4//SEC Filing
Huang James 4
Accession 0001193125-25-304018
CIK 0001604464other
Filed
Nov 30, 7:00 PM ET
Accepted
Dec 1, 5:00 PM ET
Size
12.4 KB
Accession
0001193125-25-304018
Insider Transaction Report
Form 4
Panacea Innovation Ltd
10% Owner
Transactions
- Exercise/Conversion
Common Stock
2025-11-28$0.00/sh+48,737$5→ 48,737 total(indirect: See Footnotes) - Tax Payment
Common Stock
2025-11-28$14.03/sh−1$14→ 48,736 total(indirect: See Footnotes) - Exercise/Conversion
Warrants
2025-11-28$6.61/sh−48,737$322,147→ 259,163 total(indirect: See Footnotes)Exercise: $0.00→ Common Stock (48,737 underlying)
Holdings
- 1,405,000(indirect: See Footnotes)
Common Stock
Huang James
Director10% Owner
Transactions
- Exercise/Conversion
Common Stock
2025-11-28$0.00/sh+48,737$5→ 48,737 total(indirect: See Footnotes) - Tax Payment
Common Stock
2025-11-28$14.03/sh−1$14→ 48,736 total(indirect: See Footnotes) - Exercise/Conversion
Warrants
2025-11-28$6.61/sh−48,737$322,147→ 259,163 total(indirect: See Footnotes)Exercise: $0.00→ Common Stock (48,737 underlying)
Holdings
- 1,405,000(indirect: See Footnotes)
Common Stock
Footnotes (4)
- [F1]Represents securities held by Panacea Opportunity Fund I, L.P.
- [F2]James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd. ("Fund II GP") and Panacea Opportunity Fund I GP Company, Ltd. ("Opportunity Fund GP"), which are the general partners of Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P. As a result, each of the Reporting Persons may be deemed to share beneficial ownership of the securities held of record by Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., but each disclaims such beneficial ownership.
- [F3]Represents securities held by Panacea Venture Healthcare Fund II, L.P.
- [F4]The warrants are immediately exercisable and do not expire. Pursuant to the terms of the warrants, no portion of the warrants held by a holder may be exercised to the extent that, after giving effect to the attempted exercise, such holder, together with such holder's affiliates and any other person whose beneficial ownership of the Issuer's common stock would be aggregated with such holder's for the purposes of Section 13(d) of the Exchange Act, would beneficially own in excess of 19.99% of the outstanding common stock.
Documents
Issuer
Atara Biotherapeutics, Inc.
CIK 0001604464
Entity typeother
Related Parties
1- filerCIK 0001573160
Filing Metadata
- Form type
- 4
- Filed
- Nov 30, 7:00 PM ET
- Accepted
- Dec 1, 5:00 PM ET
- Size
- 12.4 KB